How Sotyktu Works Against Psoriasis
Sotyktu (deucravacitinib) is an oral tablet approved by the FDA in 2022 for adults with moderate to severe plaque psoriasis. It targets the root cause by inhibiting a key enzyme in immune cells that drives inflammation.[1]
The drug blocks tyrosine kinase 2 (TYK2), a protein inside cells that activates inflammatory signals. TYK2 is part of the Janus kinase (JAK) family, which transmits signals from cytokines like IL-12, IL-23, and type I interferons—molecules that overstimulate T cells and keratinocytes in psoriasis, leading to red, scaly plaques.[2] Unlike broader JAK inhibitors (e.g., tofacitinib), Sotyktu binds TYK2 allosterically at a unique site, allowing it to selectively dampen psoriasis-related pathways while sparing others, potentially reducing side effects.[3]
Patients take 6 mg once daily. Clinical trials (POETYK PSO-1 and PSO-2) showed 58-59% achieved clear or almost clear skin (PASI 90) at week 16, versus 13% on placebo.[1][4]
What Happens in the Body Step by Step
1. Cytokines bind cell surface receptors.
2. TYK2 pairs with JAK2 to phosphorylate STAT proteins.
3. Activated STATs enter the nucleus, turning on genes for inflammation and skin cell overgrowth.
4. Sotyktu locks TYK2 in an inactive shape, blocking this cascade without fully shutting down the enzyme.[3]
This restores immune balance, reducing plaque formation over 4-16 weeks.
How It Compares to Other Psoriasis Treatments
| Treatment | Mechanism | Dosing | Key Differences from Sotyktu |
|-----------|-----------|--------|------------------------------|
| Biologics (e.g., Skyrizi, Tremfya) | Block IL-23 or IL-17 | Injection every 8-12 weeks | Sotyktu is oral; biologics often faster but require shots[5] |
| Other JAK inhibitors (e.g., Rinvoq) | Inhibit JAK1/TYK2 | Once daily oral | Sotyktu more TYK2-selective, lower infection risk in trials[3] |
| Topicals (e.g., Vtama) | Local PDE4 or steroid inhibition | Applied to skin | Sotyktu systemic for widespread psoriasis[1] |
Sotyktu suits patients avoiding injections; response rates match biologics long-term (52-week data).[4]
Common Side Effects and Risks Patients Report
Upper respiratory infections (20%), acne (7%), and folliculitis occur most. Serious risks include infections, malignancy, or cardiovascular events—black box warning for infections/death like other JAKs. Avoid in active infections or with strong CYP2C9 inhibitors. Not for children or pregnant patients.[1][6]
Monitoring includes baseline TB test and lipids. Real-world data shows good tolerability, but long-term cancer risk is under study.[7]
Who Makes It and Patent Timeline
Bristol Myers Squibb manufactures Sotyktu. U.S. patents extend to 2033, with pediatric exclusivity to 2034; no generics expected soon.8 DrugPatentWatch.com
Sources
[1]: FDA Label
[2]: NEJM Trial
[3]: Nature Reviews Drug Discovery
[4]: BMS POETYK Data
[5]: AAD Guidelines
[6]: Medscape Safety
[7]: JAMA Dermatology Review